Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Breast CancerEsophageal CancerGastric CancerHead and Neck CancerLung CancerOvarian CancerProstate Cancer
Interventions
DRUG

Taxotere (Docetaxel)

Taxotere is a third generation cytotoxic chemotherapy agent which is a semisynthetic taxane that inhibits cell division by promoting the rate of microtubule assembly and preventing microtubule depolymerization. It has broad antitumor activity in a range of solid tumors, and has been studied on a weekly as well as a biweekly dosing schedule.

DRUG

Alimta (Pemetrexed)

ALIMTA is a novel antifolate drug with three enzyme targets in the purine and pyrimidine synthetic pathway. It has broad activity in solid tumors and has been combined with a number of other chemotherapy agents. Its toxicity is modified by the use of continuous vitamin supplementation.

Trial Locations (1)

85724-5024

Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Arizona

OTHER

NCT01172028 - Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter